Literature DB >> 22686691

Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic alopecia.

Ann Boyapati1, Rodney Sinclair.   

Abstract

We report on a 47-year-old man who was initially treated with finasteride for androgenetic alopecia. Despite continuous treatment, after year 4 his hair density was not as good as at year 2, and low-dose dutasteride at 0.5 mg/week was added to the finasteride therapy. This resulted in a dramatic increase in his hair density, demonstrating that combined therapy with finasteride and dutasteride can improve hair density in patients already taking finasteride.
© 2012 The Authors. Australasian Journal of Dermatology © 2012 The Australasian College of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22686691     DOI: 10.1111/j.1440-0960.2012.00909.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  4 in total

Review 1.  Androgenetic Alopecia: An Update of Treatment Options.

Authors:  Yanna Kelly; Aline Blanco; Antonella Tosti
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

2.  Characterization of X-linked hypohidrotic ectodermal dysplasia (XL-HED) hair and sweat gland phenotypes using phototrichogram analysis and live confocal imaging.

Authors:  Kyle B Jones; Alice F Goodwin; Maya Landan; Kerstin Seidel; Dong-Kha Tran; Jacob Hogue; Miquella Chavez; Mary Fete; Wenli Yu; Tarek Hussein; Ramsey Johnson; Kenneth Huttner; Andrew H Jheon; Ophir D Klein
Journal:  Am J Med Genet A       Date:  2013-05-17       Impact factor: 2.802

Review 3.  Female pattern alopecia: current perspectives.

Authors:  Lauren L Levy; Jason J Emer
Journal:  Int J Womens Health       Date:  2013-08-29

4.  The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model.

Authors:  Marcello H A Da Silva; Waldemar S Costa; Francisco J B Sampaio; Diogo B De Souza
Journal:  Asian J Androl       Date:  2018 Sep-Oct       Impact factor: 3.285

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.